ES2684758T3 - Procedimiento para diagnosticar fibrosis hepática - Google Patents

Procedimiento para diagnosticar fibrosis hepática Download PDF

Info

Publication number
ES2684758T3
ES2684758T3 ES15720014.8T ES15720014T ES2684758T3 ES 2684758 T3 ES2684758 T3 ES 2684758T3 ES 15720014 T ES15720014 T ES 15720014T ES 2684758 T3 ES2684758 T3 ES 2684758T3
Authority
ES
Spain
Prior art keywords
liver fibrosis
procedure
diagnose liver
rdna
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15720014.8T
Other languages
English (en)
Inventor
Michael Courtney
Benjamin LELOUVIER
Massimo Federici
José Manuel Fernández-Real
Sandrine PAÏSSÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Vaiomer
Degli Studi Di Roma Tor Vergata, University of
Universita degli Studi di Roma Tor Vergata
Original Assignee
Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Vaiomer
Degli Studi Di Roma Tor Vergata, University of
Universita degli Studi di Roma Tor Vergata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi, Vaiomer, Degli Studi Di Roma Tor Vergata, University of, Universita degli Studi di Roma Tor Vergata filed Critical Fundacio Institut dInvestigacio Biomedica de Girona Dr Josep Trueta Idibgi
Application granted granted Critical
Publication of ES2684758T3 publication Critical patent/ES2684758T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un procedimiento in vitro para diagnosticar la fibrosis hepática en un sujeto que padece obesidad, y dicho procedimiento comprende los pasos de: a1) medir la concentración de ADNr 16S bacteriano, o la relación de la cantidad de ADNr 16S bacteriano con la cantidad de ADN total, en una muestra biológica del sujeto seleccionado del grupo que consiste en sangre, suero y muestra de plasma; y b) según el resultado de la medición en el paso a1), diagnosticar fibrosis hepática en el sujeto que padece obesidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
    imagen2
ES15720014.8T 2014-04-23 2015-04-23 Procedimiento para diagnosticar fibrosis hepática Active ES2684758T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305597 2014-04-23
EP14305597 2014-04-23
PCT/EP2015/058772 WO2015162200A1 (en) 2014-04-23 2015-04-23 Method for diagnosing hepatic fibrosis

Publications (1)

Publication Number Publication Date
ES2684758T3 true ES2684758T3 (es) 2018-10-04

Family

ID=50679975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15720014.8T Active ES2684758T3 (es) 2014-04-23 2015-04-23 Procedimiento para diagnosticar fibrosis hepática

Country Status (5)

Country Link
US (1) US10337069B2 (es)
EP (1) EP3134543B1 (es)
CN (1) CN106661617A (es)
ES (1) ES2684758T3 (es)
WO (1) WO2015162200A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3359682B1 (en) * 2015-10-09 2020-11-11 Vaiomer Method for diagnosing hepatic fibrosis based on bacterial profile and diversity
CN110229877A (zh) * 2019-06-21 2019-09-13 广东药科大学附属第一医院 一种miRNA在制备预防或诊断血脂异常肝郁证试剂中的应用
RU2759672C2 (ru) * 2019-12-12 2021-11-16 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ дифференциации причин развития фиброза печени начального уровня при хронических вирусных гепатитах В и С
CN112819786B (zh) * 2021-02-01 2023-11-28 北京精康科技有限责任公司 基于多个肝静脉波形图的肝脏血液动力检测装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007248483A1 (en) 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
US20120021421A1 (en) * 2009-02-13 2012-01-26 Jacques Amar Bacterial DNA as Markers of Cardiovascular and/or Metabolic Disease
EP2691537A1 (en) * 2011-03-31 2014-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Method for predicting abdominal obesity
WO2012131087A1 (en) * 2011-03-31 2012-10-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting insulinopenic type 2 diabetes

Also Published As

Publication number Publication date
CN106661617A (zh) 2017-05-10
US20170044612A1 (en) 2017-02-16
WO2015162200A1 (en) 2015-10-29
EP3134543A1 (en) 2017-03-01
US10337069B2 (en) 2019-07-02
EP3134543B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
CL2017001940A1 (es) Dispositivo de medición de la calidad del suelo
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112017018821A2 (pt) métodos para quantificação de níveis de insulina através de espectrometria de massa
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
BRPI0811536B8 (pt) método para detectar uma cetona biologicamente ativa e método para extração
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
MX2019011775A (es) Metodos para la cuantificacion de insulina y peptido c.
CL2017002101A1 (es) Dispositivo, plataforma y ensayo para evaluación de células
ES2564138T3 (es) Ensayo para Hemaglutinina del virus de la influenza
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
WO2013167727A3 (en) Method for determining arthritis relapse risk
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
ES2578160T3 (es) Procedimiento de diagnóstico de infecciones de sitio quirúrgico
PL396830A1 (pl) Sposób walidacji próbek w analizatorze biochemicznym i analizator biochemiczny realizujacy ten sposób
ES2566934T3 (es) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
SG10201907690TA (en) Device and method for detecting target molecules
CO6480993A2 (es) Diagnostico de una parasitosis tal como la leishmaniasis usando un extracto de proteinas ribosomicas (rpe)
MX2017002453A (es) Neprilisina como marcador pronostico de insuficiencia cardiaca.
WO2015193552A3 (en) Means and methods for determining risk of type-1 diabetes by serum protein biomarkers